



#12B
Lita

RESPONSE UNDER 37 C.F.R. § 1.116 1-6-03
EXPEDITED PROCEDURE
EXAMINING GROUP 1636

PATENT
Attorney Docket No. 204526

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Kovesdi et al.

Application No. 09/599,997

Art Unit: 1636

Examiner: McKelvey, T.

Filed: June 23, 2000

For: VIRAL VECTOR ENCODING
PIGMENT EPITHELIUM-
DERIVED FACTOR

RECEIVED
JAN 02 2003
TECH CENTER 1600/2900

AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION

Commissioner for Patents
Box AF
Washington, D.C. 20231

Dear Sir:

In response to the Final Office Action dated October 22, 2002, please enter the following amendments and consider the following remarks.

AMENDMENTS

IN THE CLAIMS:

Please cancel claims 3, 7, and 10 without prejudice.

Please replace the indicated claims with:

1. (Twice Amended) A replication deficient adenoviral vector comprising a nucleic acid sequence encoding pigment epithelium-derived factor (PEDF) or a therapeutic fragment thereof, wherein the nucleic acid sequence is operably linked to regulatory